At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 54 enrolled
Drug / intervention
DuoTrav (travoprost-timolol ophthalmic drops) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12 Week Comparison of DuoTrav and Xalacom at 24 Hours Post-Dose in the Treatment of Open-Angle Glaucoma (the DVX Study)
In Brief
A Phase 4 clinical trial evaluating DuoTrav (travoprost-timolol ophthalmic drops) and Xalacom (latanoprost-timolol ophthalmic drops) for Open-Angle Glaucoma and Ocular Hypertension. Completed, enrolled 54 participants across 2 sites.
Detailed Summary
Hypothesis: * H1: Efficacy of Duotrav will be superior to Xalacom at 24 hours post dosing when both medications are given in the morning * H2: A significant proportion of patients will prefer dosing of once daily topical fixed combination therapy in the morning compared to evening dosing
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpen-Angle Glaucoma, Ocular Hypertension
CountriesCanada
CollaboratorsAlcon Research
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2009
First PostedApr 2009
Primary CompletionNov 2009
TodayJul 2026
First PostedApr 23, 2009
Enrollment StartJan 1, 2009
Primary CompletionNov 1, 2009
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 17.2 years ago
Interventions
DuoTrav (travoprost-timolol ophthalmic drops)drug
topical ophthalmic drops instilled 1 drop daily
Xalacom (latanoprost-timolol ophthalmic drops)drug
topical ophthalmic drops instilled 1 drop daily